Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Collaborative Study Yields TB Drug Leads

ACS Meeting News: Scientists combine sets of information to identify small molecules that defeat the tuberculosis bacterium in lab studies

by Aaron A. Rowe
April 4, 2011 | A version of this story appeared in Volume 89, Issue 14

Cheminformatics firm Collaborative Drug Discovery (CDD) has used a genomic and computational approach to identify promising leads to drugs for treating tuberculosis. Doctors need new medications to fight tuberculosis because the Mycobacterium tuberculosis microbe that causes the disease is terribly good at becoming drug resistant. CDD has huge vaults of medicinal chemistry data. And Johns Hopkins University School of Medicine has a lot of data about the mycobacterium’s metabolic enzymes. By putting the two sets of information together, a research team was able to identify small molecules that can defeat the pathogen in vitro, announced CDD’s CEO, Barry A. Bunin. In the study, Johns Hopkins researchers first identified metabolic enzymes that humans don’t have and that M. tuberculosis can’t live without. Next, a scientist at CDD picked through the medicinal chemistry data looking for molecules that resemble the substrates of those enzymes. Then CDD researchers tested some of the substrate analogs on cultured tuberculosis cells. Two of the compounds from CDD’s initial screen, JFD01307SC and L-methionine-S-sulfoximine, worked well in the lab (mBio, DOI: 10.1128/mBio.00301-10). CDD scientists are now testing the compounds on a variety of tuberculosis strains in hopes they will lead to new tuberculosis medications.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.